A Multiple-Center, Randomized, Partially Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Effects of 12-Week Treatment With RO6864018 in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs RO 6864018 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 02 Oct 2017 Planned End Date changed from 28 Nov 2017 to 8 Dec 2017.
- 02 Oct 2017 Planned primary completion date changed from 28 Nov 2017 to 8 Dec 2017.
- 12 Jun 2017 Planned End Date changed from 30 Nov 2017 to 28 Nov 2017.